SCHEMBL5330339

SCHEMBL5330339

OCc1cc2cc(F)ccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
PDPK1 O15530 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
HPGD P15428 1/20 0.51
TSHR P16473 1/20 0.51
NFKB1 P19838 1/20 0.51
APEX1 P27695 1/20 0.51
CYP2C19 P33261 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
DAO P14920 1/20 0.51
IDO1 P14902 7/20 0.47
PCSK9 Q8NBP7 2/20 0.47
FLT3 P36888 3/20 0.46
TDO2 P48775 3/20 0.46
NR3C1 P04150 1/20 0.43
PGR P06401 1/20 0.43
NR3C2 P08235 1/20 0.43
HTR1A P08908 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5795144 0.85 DAO (0.51) KDM4EDAOIDO1FLT3NR3C1
SCHEMBL864817 0.84 PCSK9 (0.56) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL11159355 0.81 KDM4E (0.47) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL7896456 0.81 LOXL2 (0.62) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL187518 0.81 KDM4E (0.47) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL3838663 0.79 TSHR (0.58) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL7161852 0.78 FLT3 (0.52) FLT3RHEB
SCHEMBL27885412 0.78 PCSK9 (0.45) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL11811160 0.78 IDO1 (0.49) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL2826552 0.78 GHSR (0.49) KDM4EPDPK1ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111171040-A Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof 常州大学 2020-05-19 CN claimed
CN-106928121-B High-efficiency preparation method of 3-substituted-benzo five-membered heterocycle-2-carbonyl compound 暨南大学 2020-05-12 CN claimed
WO-2025077825-A1 METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS FAUNA BIO INCORPORATED (US) 2025-04-17 WO disclosed
CN-113474340-B Novel isoindolinone substituted indoles and derivatives as RAS inhibitors 勃林格殷格翰国际有限公司 2024-07-23 CN disclosed
EP-3931188-B1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-08-30 EP disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed
US-20220144810-A1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-12 US disclosed
EP-2714667-B1 AMINOOXAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES DESAI LAXMAN S (US) 2020-11-25 EP disclosed
EP-2714667-B1 AMINOOXAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES DESAI LAXMAN S (US) 2020-11-25 EP disclosed
CN-111171040-A Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof 常州大学 2020-05-19 CN disclosed
CN-106928121-B High-efficiency preparation method of 3-substituted-benzo five-membered heterocycle-2-carbonyl compound 暨南大学 2020-05-12 CN disclosed
US-8546400-B2 1,3-Oxazole-4-carboxamides, 1,3-Thiazole-4-carboxamides, and 1,3-Imidazole-d-carboxamides as Inhibitors of cyclin Dependent kinases Neosome Life Sciences, LLC (US) 2013-10-01 US disclosed
US-20130184288-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases Neosome Life Sciences, LLC (US) 2013-07-18 US disclosed
US-20130184288-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases Neosome Life Sciences, LLC (US) 2013-07-18 US disclosed
US-20130184288-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases Neosome Life Sciences, LLC (US) 2013-07-18 US disclosed
WO-2012166463-A2 AMINOOXAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES Neosome Life Sciences, LLC (US) 2012-12-06 WO disclosed
US-20120302578-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases Neosome Life Sciences, LLC (US) 2012-11-29 US disclosed
US-20120302578-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases Neosome Life Sciences, LLC (US) 2012-11-29 US disclosed
US-20120302578-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases Neosome Life Sciences, LLC (US) 2012-11-29 US disclosed
WO-2007046112-A1 ARYLTHIOETHER TRYPTAMINE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS SUVEN LIFE SCIENCES INC. (IN) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184288-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases CDK1, CCNK, CCNI KDM4E 324/4885PDPK1 210/4885ALDH1A1 2461/4885
US-20120302578-A1 Aminooxazole Inhibitors of Cyclin Dependent Kinases CDK1, CCNK, CCNI KDM4E 324/4885PDPK1 210/4885ALDH1A1 2461/4885
US-20220144810-A1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS NRAS, RASSF5, KRAS KDM4E 3450/4885PDPK1 1483/4885ALDH1A1 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.